Treatment Strategy Using mtor Pathway in Incurable Prostate Cancer |Biomedgrid

In spite of androgen deprivation therapy and novel hormone therapy such as enzalutamide or abiraterone has possibility of various regimens, there is still barrier to expect a complete response (CR) in castrate-resistant prostate cancer (CRPC) patients. In these cases, a new strategy using drugs targeting PI3K/AKT/mTOR pathway is necessary. In conclusion, drugs or biomarkers targeting PI3K/AKT/mTOR pathway in patients with CRPC may be used to establish a novel treatment strategy. Patients with prostate cancer are generally known to have a good prognosis; however, it is highly dependent on the risk group. Although the introduction of androgen deprivation therapy and the development of new hormone therapy drugs such as enzalutamide or abiraterone has made various treatment regimens possible, it is still difficult to expect a complete response (CR) in castrate-resistant prostate cancer (CRPC) patients. Despite of cabazitaxel development, patients who are unresponsive to docetaxel and cabazitaxel are classified as patients with incurable prostate cancer.